- Visibility 110 Views
- Downloads 75 Downloads
- Permissions
- DOI 10.18231/pjms.v.15.i.2.275-279
-
CrossMark
Elevated inflammatory markers in pre-diabetic individuals: correlation with hs-CRP & implications for cardiovascular disease prevention
- Author Details:
-
Soma Lahiri *
Soma Lahiri *
Background: Pre-diabetes is a condition characterized by elevated blood glucose levels that fall below the diagnostic thresholds for diabetes. It is a precursor to Type 2 diabetes and is associated with an increased risk of cardiovascular diseases (CVD) due to systemic inflammation. Inflammatory markers such as tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP) are known to play critical roles in the progression of insulin resistance and subsequent disease development.
Aim & Objective: To evaluate the association of inflammatory markers, including TNF-α, IL-6, and hs-CRP, with insulin resistance in pre-diabetic individuals compared to normoglycemic controls.
Materials and Methods: This study involved 60 pre-diabetic individuals and a normoglycemic control group. Insulin resistance was assessed using the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). Serum levels of TNF-α, IL-6, and hs-CRP were measured to evaluate systemic inflammation. Statistical analysis was conducted to determine the correlation between HOMA-IR and inflammatory markers, as well as the interrelationships among the markers.
Results: The study found a strong positive correlation between HOMA-IR and TNF-α (r = 0.925), as well as HOMA-IR and IL-6 (r = 0.766). A significant relationship was also observed between TNF-α and hs-CRP (r = 0.831), highlighting elevated systemic inflammation in pre-diabetic individuals.
Conclusion: The findings indicate that systemic inflammation plays a critical role in the progression of pre-diabetes to Type 2 diabetes and CVD. Inflammatory markers such as TNF-α, IL-6, and hs-CRP can serve as early indicators of disease progression. Early detection and targeted interventions focused on reducing inflammation may help prevent the transition from pre-diabetes to diabetes and mitigate cardiovascular risks, thereby improving patient outcomes.
References
- International Diabetes Federation. (2006, March 17). Diabetes Blue Circle Symbol. https://idf.org/what-we- do/awareness/merchandise/blue-circle-pin/
- Abdul-Ghani MA, Lyssenko V, Tuomi T, DeFronzo RA, Groop L. (2009). Fasting versus post-load plasma glucose concentration and the risk for future type 2 diabetes: Results from the Bothnia Study. Diabetes Care. 2009;32(2):281–6.
- Adora VR, Ratner R. Approach to the patient with prediabetes. J Clin Endocrinol Metab. 2008;93(9):3259–65.
- World Health Organization. (2013, October). Diabetes fact sheet No. 312. Retrieved March 25, 2014, from https://www.who.int
- Moreno-Aliaga M, Campion J, Milagro FI, Berjon A, Martinez JA. Adiposity and proinflammatory state: The chicken or the egg? J Adipocytes. 2005;1(1):1–16.
- Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(4):911–9.
- Vettor R, Milan G, Rossato M, Federspil G. Adipocytokines and insulin resistance. Aliment Pharmacol Ther. 2005;22(2):3–10.
- Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112(12):1821–
- Hermans MP, Levy JC, Morris RJ, Turner RC. Comparison of tests of beta-cell function across a range of glucose tolerance from normal to diabetes. Diabetes. 1999;48(9):1779–86.
- Bourlier V, Bouloumie A. Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab. 2009;35(4):251–60.
- Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860–7.
- Chiu HK, Tsai EC, Juneja R, Stoever J, Brooks-Worrell B, Goel A, et al. Equivalent insulin resistance. Diabetes Res Clin Pract. 2007;77(2):237–44.
- Fukushima M, Usami M. Insulin secretion and insulin sensitivity at different stages of glucose tolerance: A cross-sectional study of Japanese type 2 diabetes. Metabolism. 2004;53(7):831–5.
- Rudenski AS, Matthews DR. Understanding insulin resistance: Both glucose resistance and insulin resistance are required to model human diabetes. Metabolism. 1991;40(9):908–17.
- Rajala MW, Scherer PE. The adipocyte at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144(9);3765–73.
- Olefsky J, Crapo PA, Ginsberg H, Reaven GM. Metabolic effects of increased caloric intake in man. Diabetes. 1975;24(4):495–503.
- Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: Role of oxidative stress. Circulation. 2002;106(16):2067–72.
- Meshkani R, Adeli K. Hepatic insulin resistance, metabolic syndrome, and cardiovascular disease. Clin Biochem. 2009;42(13– 14);1331–46.
- Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modelling. Diabetes Care. 2004;27(6);1487–95.
- Turner R, Belfiore F, Bergman R, Molinatti G. Measurement of insulin resistance and β-cell function: The HOMA and CIGMA approach. Front Diabetes. 1993;12:66–75.
- Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985;28(7):412–21.
- Hotamisligil GS, Shargill NS. Adipose expression of tumour necrosis factor-α: Direct role in obesity-linked insulin resistance. Science. 1993;259(5091):87–91.
- Hotamisligil GS, Arner P. Increased adipose tissue expression of tumour necrosis factor-α in human obesity and insulin resistance. J Clin Investig. 1995;95(5):2409–15.
- Bastard J, Jardel C, Delattre J, Hainque B. Evidence for a link between adipose tissue interleukin-6 content and serum C-reactive protein concentrations in obese subjects. Circulation. 1999;99(16):2219–22.
- Shanmugam N, Reddy MA, Guha M, Natarajan R. High glucose- induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes. 2003;52(5):1256–64.
- Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327–34.
- Natali A, Ferrannini E. Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am. 2004;33(2):417–29.